FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Baxter Healthcare Daptomycin Recall

Daptomycin, in 0

Baxter Healthcare Corporation · Deerfield, IL

Risk level
Class II
Reported by FDA
Sep 9, 2026
Recall ID
D-0807-2026
Check your lot numberHow we source this data

Summary

Baxter Healthcare recalled Daptomycin starting Aug 6, 2026. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0807-2026 on Sep 9, 2026. Reason: CGMP Deviations. Status: Ongoing.

Why it was recalled

CGMP Deviations

Product description

Daptomycin, in 0.9% Sodium Chloride Injection, 500 mg per 50 mL (10 mg/mL), 500 mg total, in 50 mL Single Dose Container (24 bags/carton), Rx only, Sterile Nonpyrogenic, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-0714-24.

Lot numbers, UPCs & expiration codes

Lot # NC188692, Exp Date: 11/22/2027.

Where it was sold

US Nationwide; Puerto Rico; and Chile.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0807-2026
Classification
Class II
Status
Ongoing
Recall initiated
Aug 6, 2026
FDA report date
Sep 9, 2026
Quantity
N/A
Recall type
Voluntary: Firm initiated
Recalling firm
Baxter Healthcare Corporation

Original FDA data

Every field from FDA enforcement report D-0807-2026, exactly as published.

Show all FDA fields
City
Deerfield
State
IL
Status
Ongoing
Country
United States
Event ID
99500
Address
1 Baxter Pkwy
Code information
Lot # NC188692, Exp Date: 11/22/2027.
Postal code
60015-4625
Report date
Sep 9, 2026
Product type
Drugs
Recall number
D-0807-2026
Classification
Class II
Recalling firm
Baxter Healthcare Corporation
Reason for recall
CGMP Deviations
Voluntary / mandated
Voluntary: Firm initiated
Product description
Daptomycin, in 0.9% Sodium Chloride Injection, 500 mg per 50 mL (10 mg/mL), 500 mg total, in 50 mL Single Dose Container (24 bags/carton), Rx only, Sterile Nonpyrogenic, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-0714-24.
Distribution pattern
US Nationwide; Puerto Rico; and Chile.
Recall initiation date
Aug 6, 2026
Initial firm notification
Letter
Center classification date
Aug 28, 2026

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0807-2026, published Sep 9, 2026. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls